PT-141

Background

Bremelanotide (PT-141, Vyleesi) is a synthetic cyclic heptapeptide melanocortin receptor agonist developed from the melanotan II scaffold, originally investigated for its pigmentary and erectile effects.[7][8] It belongs to the melanocortin class of peptides, derived from the endogenous agonist α-melanocyte-stimulating hormone (α-MSH), which acts on G protein–coupled melanocortin receptors (MCRs).[7][10] Early work on melanotan II showed unexpected pro‑erectile and pro‑sexual effects, leading to the development of PT‑141 as a more selective and better tolerated derivative.[7][8]

Preclinical studies in rodents established that PT‑141 facilitated sexual solicitation behavior in female rats without non‑specific increases in locomotion or stereotypy, supporting a central pro‑sexual mechanism.[13] Subsequent early clinical studies in men with erectile dysfunction (ED) and women with sexual arousal or desire disorders demonstrated changes in subjective sexual response and erectile function, prompting larger trials.[1][3][8]

In 2019, the U.S. Food and Drug Administration (FDA) approved bremelanotide (Vyleesi) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as an on‑demand subcutaneous injection.[11][12][15] As of the latest regulatory reports, there is no EMA marketing authorization; use in the European Union remains investigational.

Mechanism of action

Bremelanotide is a non‑selective melanocortin receptor agonist, with principal activity at MC3R and MC4R, which are widely expressed in the central nervous system and involved in energy homeostasis, autonomic regulation, and sexual behavior.[7][8][10] Structural work on MC4R shows how melanocortin peptides engage the orthosteric pocket and activate Gs‑coupled signaling, leading to cyclic AMP production and downstream neuronal effects.[6]

In sexual function, MC4R‑expressing neurons in the hypothalamus and other brain regions integrate excitatory and inhibitory influences on sexual desire and arousal.[8][10][12] Activation of these melanocortin pathways is thought to:

• Enhance pro‑sexual excitatory neurotransmission (e.g., via dopaminergic pathways) and reduce inhibitory tone.[8][10][12]
• Modulate central autonomic outflow relevant to genital vasocongestion and erectile response.[8][10]

Unlike phosphodiesterase type‑5 (PDE5) inhibitors, which act peripherally on penile cavernosal smooth muscle, bremelanotide acts predominantly centrally, upstream of peripheral vasodilatory pathways.[8][10] Preclinical models indicate that PT‑141 facilitates sexual solicitation behaviors in female rats without altering lordosis reflexes, suggesting a selective effect on motivational aspects of sexual behavior.[13]

Evidence summary

Preclinical evidence

In a seminal rodent study, Pfaus et al. evaluated PT‑141 in ovariectomized, hormone‑primed female rats and observed a selective increase in sexual solicitation behaviors (hops and darts, ear wiggling) at doses that did not affect lordosis or general activity, supporting a specific pro‑motivational sexual effect via central melanocortin receptors.[13]

Broader reviews of melanocortins in sexual dysfunction summarized multiple animal models where melanotan II and PT‑141 increased penile erections, copulatory behavior, and sexual motivation in both sexes, consistent with MC3R/MC4R‑mediated facilitation of central arousal pathways.[8][10]

Early human studies

An early randomized, double‑blind, placebo‑controlled phase 2 study in premenopausal women with female sexual arousal disorder (FSAD) evaluated subcutaneous bremelanotide and found significant improvements in subjective sexual arousal and desire compared with placebo on validated psychometric instruments.[1][3] The published trial (Clayton et al., Journal of Sexual Medicine, 2006) reported that single doses of bremelanotide administered before sexual activity improved several items on the Female Sexual Function Index and a Subjective Sexual Arousal Scale compared with placebo, with nausea and flushing as the most common adverse events.[3]

Early trials in men with ED demonstrated that subcutaneous or intranasal PT‑141 produced dose‑dependent increases in erectile response sufficient for intercourse in a substantial proportion of participants, including some non‑responders to PDE5 inhibitors, though development in male ED did not proceed to approval.[7][8]

Phase 2–3 HSDD studies in women

Two pivotal, randomized, double‑blind, placebo‑controlled phase 3 trials (RECONNECT studies) evaluated on‑demand subcutaneous bremelanotide in premenopausal women with acquired, generalized HSDD.[12][14] Each trial enrolled several hundred women (individual trial sample sizes on the order of 600–700 participants; combined safety population >1,200).[12][14]

Key design features included self‑administered 1.75 mg subcutaneous injections as needed before anticipated sexual activity (with limits on maximum frequency) over ~24 weeks.[12] The co‑primary endpoints were change from baseline in:

• Female Sexual Function Index–Desire (FSFI‑D) domain score, and
• Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS‑DAO) Item 13 (distress related to low sexual desire).[12]

Across the two trials, bremelanotide produced statistically significant mean improvements in FSFI‑D (approximately +0.3 to +0.4 points vs placebo) and FSDS‑DAO Item 13 (reductions of approximately −0.3 to −0.4 points vs placebo), with a higher proportion of responders (pre‑specified composite of desire improvement and distress reduction) in the active group.[12] Effect sizes were modest but clinically relevant for a subset of patients.[12][15]

Long‑term extension

An open‑label, 52‑week extension of the RECONNECT program assessed long‑term safety and durability of response in women who had completed the phase 3 trials.[14] Several hundred women received bremelanotide 1.75 mg subcutaneously as needed over one year, with typical use averaging a few doses per month.[14]

The extension confirmed the maintenance of efficacy on FSFI‑D and FSDS‑DAO endpoints in continued users, with no new safety signals beyond those observed in the controlled trials.[14] Nausea remained the most common adverse event, usually occurring with early doses and decreasing over time.[14]

Reviews and pharmacokinetic work

Narrative and focused reviews in sexual medicine summarize the clinical trial data, emphasizing that bremelanotide offers an on‑demand, centrally acting option for premenopausal women with HSDD, with modest effect sizes and a tolerability profile dominated by gastrointestinal and cardiovascular effects (transient blood pressure increases).[12][15] A recent analytical study in beagle dogs demonstrated that oral bremelanotide has minimal oral bioavailability, reinforcing the rationale for parenteral routes such as subcutaneous injection or intranasal formulations.[2]

Clinical and research uses

Approved indication

In the United States, bremelanotide is approved as Vyleesi for:

• Treatment of acquired, generalized HSDD in premenopausal women, to be used on an as‑needed basis prior to anticipated sexual activity.[11][12][15]

The indication excludes women with:

• HSDD due to co‑existing medical or psychiatric conditions,
• Relationship problems, or
• Effects of medications or other substances.[12][15]

Off‑label and investigational contexts

Bremelanotide and related melanocortin agonists have been explored, but not approved, in:

• Male erectile dysfunction, including in PDE5 non‑responders, with evidence of improved erectile response and intercourse rates.[7][8]
• Female sexual arousal disorder (FSAD) and mixed female sexual dysfunction phenotypes.[1][3][8]
• Experimental IV and intranasal formulations for ED and sexual dysfunction, as summarized in recent narrative reviews of peptide therapies.[4][5]

These applications remain investigational or off‑label, with limited controlled data and no regulatory approval.

Dosing context

Published product information and clinical trials describe an on‑demand subcutaneous dosing regimen for HSDD:[12][14][15]

• Nominal dose: 1.75 mg subcutaneously, typically into the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity.[12][15]
• Frequency limits: No more than one dose within 24 hours and no more than eight doses per month, to mitigate risk of adverse effects including blood pressure elevations and nausea.[12][15]

These parameters describe clinical trial and label‑based usage patterns and do not constitute individualized dosing recommendations.

Experimental work in beagle dogs confirms that oral dosing yields negligible systemic exposure due to poor absorption, supporting the continued use of parenteral routes.[2] Intranasal formulations were used in early development but are not part of the current approved product.[7][8]

Safety profile

Common adverse effects

Across phase 2 and 3 trials and long‑term extension studies, the most frequently reported adverse events include:[12][14][15]

• Nausea (often dose‑related, typically early in treatment; can be severe in a minority of patients)
• Vomiting
• Flushing and hot flush
• Headache
• Injection site reactions (pain, erythema)

Nausea is the leading cause of treatment discontinuation.[12][14][15]

Cardiovascular effects

Bremelanotide can cause transient increases in blood pressure (systolic and diastolic) and small decreases in heart rate following injection.[11][12][15] These changes typically peak within a few hours and return to baseline within 12 hours, but the drug is contraindicated in uncontrolled hypertension or known cardiovascular disease due to potential risk.[11][12]

Clinical trials excluded high‑risk cardiovascular patients, so evidence in this population is limited.[12] Regulatory labeling recommends avoiding use in patients at high cardiovascular risk and monitoring blood pressure during therapy, particularly in the early phase of treatment.[11][12]

Other safety considerations

• Hyperpigmentation: As a melanocortin agonist, bremelanotide may cause focal skin hyperpigmentation, especially in exposed areas or those with pre‑existing nevi or freckles, particularly with frequent dosing.[12][15]
• Drug interactions: Formal interaction studies are limited; given its central mechanism and peptide structure, classical CYP‑mediated interactions are not prominent, but caution is recommended with medications affecting blood pressure or heart rate.[12][15]
• Pregnancy and lactation: Clinical trials were conducted in premenopausal women using effective contraception; there are insufficient data in pregnancy or lactation, and use is not recommended in these settings.[12][15]

Overall, long‑term extension data up to 52 weeks suggest a stable safety profile without evidence of cumulative toxicity, though long‑term cardiovascular outcome data are lacking.[14]

Regulatory status

United States

The FDA approved bremelanotide (Vyleesi) in 2019 for on‑demand treatment of acquired, generalized HSDD in premenopausal women.[11][12] The approval followed review of the two pivotal RECONNECT phase 3 trials and the 52‑week safety extension.[12][14] Post‑marketing surveillance recommendations focus on cardiovascular safety, nausea‑related discontinuations, and skin hyperpigmentation.[11]

European Union and other regions

As of current published reviews, bremelanotide does not have EMA marketing authorization, and its availability in the EU is limited to clinical trials or unlicensed/off‑label channels where national regulations allow.[12][15] Reviews of therapeutic peptides in sexual medicine note bremelanotide’s FDA approval but do not describe parallel approvals in Europe.[5][15]

Regulatory status in other regions (e.g., Canada, Asia‑Pacific, Latin America) is heterogeneous and evolving; clinicians and researchers typically consult local regulatory databases for the most current information.